Organizing empyema induced in mice by Streptococcus pneumoniae: effects of plasminogen activator inhibitor-1 deficiency

被引:18
|
作者
Tucker, Torry A. [1 ]
Jeffers, Ann [1 ]
Boren, Jake [1 ]
Quaid, Brandon [1 ]
Owens, Shuzi [1 ]
Koenig, Kathleen B. [1 ]
Tsukasaki, Yoshikazu [1 ]
Florova, Galina [1 ]
Komissarov, Andrey A. [1 ]
Ikebe, Mitsuo [1 ]
Idell, Steven [1 ]
机构
[1] Univ Texas Hlth Sci Ctr Tyler, Dept Cellular & Mol Biol, 11937 US HWY 271,Biomed Res Bldg,Lab C-5, Tyler, TX 75708 USA
来源
关键词
Pleural mesothelial cells; Pneumonia; Plasminogen activator inhibitor-1;
D O I
10.1186/s40169-016-0097-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pleural infection affects about 65,000 patients annually in the US and UK. In this and other forms of pleural injury, mesothelial cells (PMCs) undergo a process called mesothelial (Meso) mesenchymal transition (MT), by which PMCs acquire a profibrogenic phenotype with increased expression of a-smooth muscle actin (a-SMA) and matrix proteins. MesoMT thereby contributes to pleural organization with fibrosis and lung restriction. Current murine empyema models are characterized by early mortality, limiting analysis of the pathogenesis of pleural organization and mechanisms that promote MesoMT after infection. Methods: A new murine empyema model was generated in C57BL/6 J mice by intrapleural delivery of Streptococcus pneumoniae (D39, 3 x 10(7)-5 x 10(9) cfu) to enable use of genetically manipulated animals. CT-scanning and pulmonary function tests were used to characterize the physiologic consequences of organizing empyema. Histology, immunohistochemistry, and immunofluorescence were used to assess pleural injury. ELISA, cytokine array and western analyses were used to assess pleural fluid mediators and markers of MesoMT in primary PMCs. Results: Induction of empyema was done through intranasal or intrapleural delivery of S. pneumoniae. Intranasal delivery impaired lung compliance (p < 0.05) and reduced lung volume (p < 0.05) by 7 days, but failed to reliably induce empyema and was characterized by unacceptable mortality. Intrapleural delivery of S. pneumoniae induced empyema by 24 h with lung restriction and development of pleural fibrosis which persisted for up to 14 days. Markers of MesoMT were increased in the visceral pleura of S. pneumoniae infected mice. KC, IL-17A, MIP-1 beta, MCP-1, PGE(2) and plasmin activity were increased in pleural lavage of infected mice at 7 days. PAI-1(-/-) mice died within 4 days, had increased pleural inflammation and higher PGE2 levels than WT mice. PGE2 was induced in primary PMCs by uPA and plasmin and induced markers of MesoMT. Conclusion: To our knowledge, this is the first murine model of subacute, organizing empyema. The model can be used to identify factors that, like PAI-1 deficiency, alter outcomes and dissect their contribution to pleural organization, rind formation and lung restriction.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] PLASMINOGEN-ACTIVATOR INHIBITOR-1
    LOSKUTOFF, DJ
    MIMURO, J
    HEKMAN, C
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 534 - 534
  • [22] Role of plasminogen activator inhibitor-1 in glucocorticoid-induced muscle change in mice
    Yukinori Tamura
    Naoyuki Kawao
    Takeshi Shimoide
    Kiyotaka Okada
    Osamu Matsuo
    Hiroshi Kaji
    Journal of Bone and Mineral Metabolism, 2018, 36 : 148 - 156
  • [23] Plasminogen activator inhibitor-1 and Restenosis
    Garg, Nadish
    Fay, William P.
    CURRENT DRUG TARGETS, 2007, 8 (09) : 1003 - 1006
  • [24] Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury
    Ma, J
    Weisberg, A
    Griffin, JP
    Vaughan, DE
    Fogo, AB
    Brown, NJ
    KIDNEY INTERNATIONAL, 2006, 69 (06) : 1064 - 1072
  • [25] Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced renal injury
    Ma, J
    Weisberg, A
    Griffin, JP
    Vaughan, DE
    Fogo, AB
    Brown, NJ
    HYPERTENSION, 2004, 44 (04) : 514 - 514
  • [26] Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients
    Lindgren, A
    Lindoff, C
    Norrving, B
    Astedt, B
    Johansson, BB
    STROKE, 1996, 27 (06) : 1066 - 1071
  • [27] Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients
    Nomura, Shosaku
    Taniura, Takehito
    Shouzu, Akira
    Omoto, Seitarou
    Inami, Norihito
    Fujita, Shinya
    Tamaki, Takeshi
    Yokoi, Takashi
    Shimizu, Toshiki
    Ito, Tomoki
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2012, 5 : 535 - 540
  • [28] BIOLOGICAL EFFECTS OF COMBINED INACTIVATION OF PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE-FUNCTION IN MICE
    LIJNEN, HR
    MOONS, L
    BEELEN, V
    CARMELIET, P
    COLLEN, D
    THROMBOSIS AND HAEMOSTASIS, 1995, 74 (04) : 1126 - 1131
  • [29] Effects of Plasminogen Activator Inhibitor-1 on the Circadian Clock in Liver
    Wilsbacher, Lisa D.
    Levine, Joshua A.
    Eren, Mesut
    Shang, Meng
    Kalousdian, Anthony
    Vaughan, Douglas E.
    CIRCULATION, 2022, 146
  • [30] Solvent effects on activity and conformation of plasminogen activator inhibitor-1
    Andreasen, PA
    Egelund, R
    Jensen, S
    Rodenburg, KW
    THROMBOSIS AND HAEMOSTASIS, 1999, 81 (03) : 407 - 414